Published in Steroids on March 09, 2009
Peptidomimetic targeting of critical androgen receptor-coregulator interactions in prostate cancer. Nat Commun (2013) 2.11
Androgen receptor signaling in prostate cancer development and progression. J Carcinog (2011) 1.90
Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover. Proc Natl Acad Sci U S A (2013) 1.66
Mechanisms of androgen receptor activation in castration-resistant prostate cancer. Endocrinology (2013) 1.12
Targeting 5α-reductase for prostate cancer prevention and treatment. Nat Rev Urol (2011) 1.06
Research resource: expression profiling reveals unexpected targets and functions of the human steroid receptor RNA activator (SRA) gene. Mol Endocrinol (2010) 1.01
Androgen receptor abnormalities in castration-recurrent prostate cancer. Expert Rev Endocrinol Metab (2009) 0.97
TBLR1 as an androgen receptor (AR) coactivator selectively activates AR target genes to inhibit prostate cancer growth. Endocr Relat Cancer (2014) 0.92
Targeted disruption of the p160 coactivator interface of androgen receptor (AR) selectively inhibits AR activity in both androgen-dependent and castration-resistant AR-expressing prostate cancer cells. Int J Biochem Cell Biol (2012) 0.89
Androgen receptor gene rearrangements: new perspectives on prostate cancer progression. Curr Drug Targets (2013) 0.85
The lncRNA SLNCR1 Mediates Melanoma Invasion through a Conserved SRA1-like Region. Cell Rep (2016) 0.85
Androgen receptor footprint on the way to prostate cancer progression. World J Urol (2011) 0.80
RhoGDIα downregulates androgen receptor signaling in prostate cancer cells. Prostate (2013) 0.80
Loss of the NKX3.1 tumorsuppressor promotes the TMPRSS2-ERG fusion gene expression in prostate cancer. BMC Cancer (2014) 0.79
Moving Beyond the Androgen Receptor (AR): Targeting AR-Interacting Proteins to Treat Prostate Cancer. Horm Cancer (2016) 0.77
Nonalcoholic steatohepatitis-related hepatocellular carcinoma: is there a role for the androgen receptor pathway? Onco Targets Ther (2017) 0.75
YAP1 and AR interactions contribute to the switch from androgen-dependent to castration-resistant growth in prostate cancer. Nat Commun (2015) 0.75
Influence of ovarian endometrioma on expression of steroid receptor RNA activator, estrogen receptors, vascular endothelial growth factor, and thrombospondin 1 in the surrounding ovarian tissues. Reprod Sci (2013) 0.75
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science (2005) 39.06
Molecular determinants of resistance to antiandrogen therapy. Nat Med (2003) 18.90
Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science (1995) 10.42
A steroid receptor coactivator, SRA, functions as an RNA and is present in an SRC-1 complex. Cell (1999) 4.65
Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res (2006) 4.50
Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev (2007) 3.54
Sharp, an inducible cofactor that integrates nuclear receptor repression and activation. Genes Dev (2001) 2.68
Retracted A subfamily of RNA-binding DEAD-box proteins acts as an estrogen receptor alpha coactivator through the N-terminal activation domain (AF-1) with an RNA coactivator, SRA. EMBO J (2001) 2.21
Activation of the human androgen receptor through a protein kinase A signaling pathway. J Biol Chem (1996) 2.15
Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression. Cancer Res (2005) 2.14
SRC-3 is required for prostate cancer cell proliferation and survival. Cancer Res (2005) 2.07
Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer. Cancer Res (2006) 1.90
High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy. Am J Surg Pathol (2004) 1.61
Steroid receptor coactivator-3 and activator protein-1 coordinately regulate the transcription of components of the insulin-like growth factor/AKT signaling pathway. Cancer Res (2006) 1.61
SLIRP, a small SRA binding protein, is a nuclear receptor corepressor. Mol Cell (2006) 1.57
From estrogen to androgen receptor: a new pathway for sex hormones in prostate. Proc Natl Acad Sci U S A (1998) 1.45
Repressors of androgen and progesterone receptor action. J Biol Chem (2003) 1.35
Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells. Proc Natl Acad Sci U S A (1998) 1.33
Steroid receptor RNA activator stimulates proliferation as well as apoptosis in vivo. Mol Cell Biol (2003) 1.22
A novel steroid receptor co-activator protein (SRAP) as an alternative form of steroid receptor RNA-activator gene: expression in prostate cancer cells and enhancement of androgen receptor activity. Biochem J (2003) 1.15
Target gene-specific regulation of androgen receptor activity by p42/p44 mitogen-activated protein kinase. Mol Endocrinol (2008) 1.03
Antiandrogen treatments in locally advanced prostate cancer: are they all the same? J Cancer Res Clin Oncol (2006) 0.82
Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression. Cancer Res (2005) 2.14
Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer. Cancer Res (2006) 1.90
Androgen receptor action in hormone-dependent and recurrent prostate cancer. J Cell Biochem (2006) 1.85
International Union of Pharmacology. LXV. The pharmacology and classification of the nuclear receptor superfamily: glucocorticoid, mineralocorticoid, progesterone, and androgen receptors. Pharmacol Rev (2006) 1.60
Regulation of Bcl-2 expression by dihydrotestosterone in hormone sensitive LNCaP-FGC prostate cancer cells. J Urol (2003) 1.51
Cyclin-dependent kinase activity is required for progesterone receptor function: novel role for cyclin A/Cdk2 as a progesterone receptor coactivator. Mol Cell Biol (2005) 1.41
Repressors of androgen and progesterone receptor action. J Biol Chem (2003) 1.35
Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat (2009) 1.35
Decreased expression and androgen regulation of the tumor suppressor gene INPP4B in prostate cancer. Cancer Res (2011) 1.32
Quantifying effects of ligands on androgen receptor nuclear translocation, intranuclear dynamics, and solubility. J Cell Biochem (2006) 1.31
Androgen receptors in hormone-dependent and castration-resistant prostate cancer. Pharmacol Ther (2013) 1.28
Human progesterone receptor displays cell cycle-dependent changes in transcriptional activity. Mol Cell Biol (2005) 1.25
Steroid receptor phosphorylation: Assigning function to site-specific phosphorylation. Biofactors (2009) 1.13
Androgen receptor coactivators and prostate cancer. Adv Exp Med Biol (2008) 1.12
Androgen receptor signaling and vitamin D receptor action in prostate cancer cells. Prostate (2005) 1.06
Target gene-specific regulation of androgen receptor activity by p42/p44 mitogen-activated protein kinase. Mol Endocrinol (2008) 1.03
A germline variation in the progesterone receptor gene increases transcriptional activity and may modify ovarian cancer risk. J Clin Endocrinol Metab (2004) 1.03
Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression. Int J Oncol (2012) 1.02
p53 Is required for 1,25-dihydroxyvitamin D3-induced G0 arrest but is not required for G1 accumulation or apoptosis of LNCaP prostate cancer cells. Endocrinology (2003) 1.00
Androgen receptor splice variants are resistant to inhibitors of Hsp90 and FKBP52, which alter androgen receptor activity and expression. Steroids (2013) 0.99
1Alpha,25-dihydroxyvitamin D3 reduces c-Myc expression, inhibiting proliferation and causing G1 accumulation in C4-2 prostate cancer cells. Endocrinology (2009) 0.99
Vitamin D and prostate cancer. Exp Biol Med (Maywood) (2004) 0.99
Mechanistic differences in the activation of estrogen receptor-alpha (ER alpha)- and ER beta-dependent gene expression by cAMP signaling pathway(s). J Biol Chem (2003) 0.97
Vitamin D and prostate cancer. J Androl (2002) 0.97
The functional consequences of cross-talk between the vitamin D receptor and ERK signaling pathways are cell-specific. J Biol Chem (2004) 0.96
Cyclin dependent kinase 2 and the regulation of human progesterone receptor activity. Steroids (2007) 0.95
Parathyroid hormone-related protein regulates cell survival pathways via integrin alpha6beta4-mediated activation of phosphatidylinositol 3-kinase/Akt signaling. Mol Cancer Res (2009) 0.94
c-Jun N-terminal kinase contributes to aberrant retinoid signaling in lung cancer cells by phosphorylating and inducing proteasomal degradation of retinoic acid receptor alpha. Mol Cell Biol (2005) 0.93
Metabolomic profiling identifies biochemical pathways associated with castration-resistant prostate cancer. J Proteome Res (2013) 0.92
Role of insulin-like growth factor binding proteins in 1alpha,25-dihydroxyvitamin D(3)-induced growth inhibition of human prostate cancer cells. Prostate (2005) 0.91
Inhibition of proliferation and induction of apoptosis by 25-hydroxyvitamin D3-3beta-(2)-Bromoacetate, a nontoxic and vitamin D receptor-alkylating analog of 25-hydroxyvitamin D3 in prostate cancer cells. Clin Cancer Res (2004) 0.91
Dual roles for the phosphatase PPM1D in regulating progesterone receptor function. J Biol Chem (2005) 0.91
AR collaborates with ERα in aromatase inhibitor-resistant breast cancer. Breast Cancer Res Treat (2014) 0.90
Novel phosphorylation target in the serum response factor MADS box regulates alpha-actin transcription. Biochemistry (2003) 0.90
EB1089 inhibits the parathyroid hormone-related protein-enhanced bone metastasis and xenograft growth of human prostate cancer cells. Mol Cancer Ther (2009) 0.90
Akt phosphorylates and suppresses the transactivation of retinoic acid receptor alpha. Biochem J (2006) 0.90
Targeted disruption of the p160 coactivator interface of androgen receptor (AR) selectively inhibits AR activity in both androgen-dependent and castration-resistant AR-expressing prostate cancer cells. Int J Biochem Cell Biol (2012) 0.89
Constitutively active FOXO1a and a DNA-binding domain mutant exhibit distinct co-regulatory functions to enhance progesterone receptor A activity. J Mol Endocrinol (2007) 0.88
1{alpha},25-Dihydroxyvitamin D3 inhibits growth of VCaP prostate cancer cells despite inducing the growth-promoting TMPRSS2:ERG gene fusion. Endocrinology (2010) 0.88
Prostate cancer cell type-specific involvement of the VDR and RXR in regulation of the human PTHrP gene via a negative VDRE. Steroids (2005) 0.87
Identification of a transferable two-amino-acid motif (GT) present in the C-terminal tail of the human lutropin receptor that redirects internalized G protein-coupled receptors from a degradation to a recycling pathway. Mol Endocrinol (2002) 0.87
Phosphorylation: a fundamental regulator of steroid receptor action. Trends Endocrinol Metab (2013) 0.86
Regulation of progesterone receptor activity by cyclin dependent kinases 1 and 2 occurs in part by phosphorylation of the SRC-1 carboxyl-terminus. Int J Biochem Cell Biol (2011) 0.85
Partial agonist activity of the progesterone receptor antagonist RU486 mediated by an amino-terminal domain coactivator and phosphorylation of serine400. Mol Endocrinol (2009) 0.85
PTHrP contributes to the anti-proliferative and integrin alpha6beta4-regulating effects of 1,25-dihydroxyvitamin D(3). Steroids (2007) 0.84
Vitamin D receptor agonists induce prostatic acid phosphatase to reduce cell growth and HER-2 signaling in LNCaP-derived human prostate cancer cells. J Steroid Biochem Mol Biol (2005) 0.82
A novel androgen receptor mutant, A748T, exhibits hormone concentration-dependent defects in nuclear accumulation and activity despite normal hormone-binding affinity. Mol Endocrinol (2002) 0.82
1α,25-dihydroxyvitamin D3 inhibits C4-2 prostate cancer cell growth via a retinoblastoma protein (Rb)-independent G1 arrest. Prostate (2011) 0.81
Differential skeletal responses of hindlimb unloaded rats on a vitamin D-deficient diet to 1,25-dihydroxyvitamin D3 and its analog, seocalcitol (EB1089). Bone (2004) 0.81
A standards-based, peer-reviewed teaching award to enhance a medical school's teaching environment and inform the promotions process. Acad Med (2012) 0.80
Analysis of receptor phosphorylation. Methods Enzymol (2003) 0.80
Stable expression of full length human androgen receptor in PC-3 prostate cancer cells enhances sensitivity to retinoic acid but not to 1alpha,25-dihydroxyvitamin D3. Prostate (2003) 0.79
Molecular analysis of the androgen receptor in ten prostate cancer specimens obtained before and after androgen ablation. J Androl (2003) 0.78
1alpha,25-dihydroxyvitamin D3 induced growth inhibition of PC-3 prostate cancer cells requires an active transforming growth factor beta signaling pathway. Prostate (2004) 0.78
The prostate cancer TMPRSS2:ERG fusion synergizes with the vitamin D receptor (VDR) to induce CYP24A1 expression-limiting VDR signaling. Endocrinology (2014) 0.77
A role for site-specific phosphorylation of mouse progesterone receptor at serine 191 in vivo. Mol Endocrinol (2014) 0.75